Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01477489

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

Study identifier: NCT01477489
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

Breast cancer with either

a) locoregional recurrence after previous mastectomy or,
b) inflammatory breast cancer status post mastectomy for which radiotherapy to the chest wall and regional nodes is planned as part of treatment.
Patients with Stage IV disease are eligible as long as they meet these criteria.

Type of study:

Phase I study

Treatment:

Veliparib twice daily and standard radiation treatment

Study sites:

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Nicole Ryabin 617-632-6767 nryabin@partners.org
Contact: Jennifer Bellon 617-632-3591 jbellon@partners.org

Michigan
Ann Arbor
University of Michigan
Contact: Cancer Answer Line 800-865-1125 canceranswerline@umich.edu
Contact: Michelle Castle 734-615-8492 michcast@med.umich.edu

New York
New York City
Memorial Sloan Ketter Cancer Center

Contact: Dr. Beryl McCormick: 212-639-6756 mccormib@mskcc.org

Page updated 07/08/13